ArticleScientific reports2023
Inhibition of cell cycle-dependent hyphal and biofilm formation by a novel cytochalasin 19,20‑epoxycytochalasin Q in Candida albicans.
Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 20 citations in OpenAlex.
- The complex subunit VdAP-2α regulates polar growth, ergosterol metabolism, and virulence inVirulence · 2026Article
- Functional analysis ofmBio · 2026Article
- Antibiofilm and anti-hyphal activity of a valencene-enriched fraction against Candida albicans.Archives of microbiology · 2026Article
- Overcoming Candida albicans biofilm drug resistance via azole-sophorolipid synergy.Scientific reports · 2026Article
- Clearing Candida biofilms using combined antimicrobial sophorolipids with amphotericin B and itraconazole.FEMS yeast research · 2026Article
- Optimizing carbon-to-nitrogen ratios for enhanced antimicrobial sophorolipid production in Starmerella riodocensis GT-SL1R.FEMS yeast research · 2026Article
- Fluorene derivatives as potent antifungal and antibiofilm agents against fluconazole-resistantBiofilm · 2025Article
- The dual antifungal and antibiofilm activities of β-carotene against multidrug-resistant Candida albicans induce wound healing in a diabetic rat model: an in vitro and in vivo study.BMC microbiology · 2025Article
- Microbial Biofilms: Where Are We and Where Are We Going?The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2025Article
- Yeast-derived glycolipids disrupt Candida biofilm and inhibit expression of genes in cell adhesion.Scientific reports · 2025Article
- Elucidating a novel metabolic pathway for enhanced antimicrobial glycolipid biosurfactant production in the yeast Meyerozyma guilliermondii.Scientific reports · 2025Article
- Antifungal Polyacetylenic Deoxyglycosides Isolated from Endophytic FungusJournal of fungi (Basel, Switzerland) · 2025Article
- The appropriate nutrient conditions for methicillin-resistant Staphylococcus aureus and Candida albicans dual-species biofilm formation in vitro.Scientific reports · 2025Article
- Amphotericin B Ocular Films for Fungal Keratitis and a Novel 3D-Printed Microfluidic Ocular Lens Infection Model.Journal of fungi (Basel, Switzerland) · 2024Article
- Rosmarinic Acid Exhibits Antifungal and Antibiofilm Activities AgainstJournal of fungi (Basel, Switzerland) · 2024Article
- Exploring Non-Thermal Plasma and UV Radiation as Biofilm Control Strategies against Foodborne Filamentous Fungal Contaminants.Foods (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biofilm-mediated drug resistance is a key virulence factor of pathogenic microbes that cause a serious global health threat especially in immunocompromised individuals. Here, we investigated the antihyphal and antibiofilm activity of 19,20‑epoxycytochalasin Q (ECQ), a cytochalasin actin inhibitor isolated from medicinal mushroom Xylaria sp. BCC1067 against Candida albicans. Remarkably, 256 µg/ml of ECQ inhibited over 95% of C. albicans hyphal formation after 24 h-treatment. Combined ECQ and lipid-based biosurfactant effectively enhanced the antihyphal activity, lowering required ECQ concentrations. Hyphal fragmentation and reduction of biofilm biomass, shown by SEM and AFM visualization of ECQ-treated biofilms, were well corelated to the reduced metabolic activities of young and 24 h-preformed C. albicans biofilms. Induced intracellular accumulation of reactive oxygen species (ROS) also occurred in accompany with the leakage of shrunken cell membrane and defective cell wall at increasing ECQ concentrations. Transcriptomic analyses via RNA-sequencing revealed a massive change (> 1300 genes) in various biological pathways, following ECQ-treatment. Coordinated expression of genes, associated with cellular response to drugs, filamentous growth, cell adhesion, biofilm formation, cytoskeleton organization, cell division cycle, lipid and cell wall metabolisms was confirmed via qRT-PCR. Protein-protein association tool identified coupled expression between key regulators of cell division cyclin-dependent kinases (Cdc19/28) and a gamma-tubulin (Tub4). They coordinated ECQ-dependent hyphal specific gene targets of Ume6 and Tec1 during different phases of cell division. Thus, we first highlight the antihyphal and antibiofilm property of the novel antifungal agent ECQ against one of the most important life-threatening fungal pathogens by providing its key mechanistic detail in biofilm-related fungal infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.